Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 279 results for "cipla"

Cipla allots equity shares

Under ESOS Business Standard, 1 day ago

162 images for cipla

Sify, 17 hours ago
Sify, 4 days ago
NDTV Profit, 1 week ago
India Infoline, 1 week ago
MSN News US, 1 week ago
Livemint.com, 1 week ago
India Infoline, 2 weeks ago
Livemint.com, 1 week ago
India Infoline, 2 weeks ago
Rediff.com, 1 week ago
Rediff.com

Why Cipla's 'successor' decided to quit

A football fan, Kamil Hamied is known to be a calm and quiet person who wants to do something for society, like his uncle Yusuf.  Image: Kamil Hamied keen to pursue other interests.     Kamil Hamied, the 33-year-old scion of Cipla, has quit the pharmaceutical major at a time when the family patriarch, Cipla Chairman Yusuf Hamied, was finalising the plans to anoint him his successor and was grooming him to take over the reins of the company.  The reason for this sudden and ...
 Rediff.com1 week ago Newsmaker: Kamil Hamied  Business Standard1 week ago What has Kamil Hamied quit Cipla?  India Infoline1 week ago Successor-in-waiting Kamil Hamied leaves Cipla to pursue his own interests  Economic Times1 week ago
India Infoline

Bulls Technical --Sensex rises over 150 pts, Nifty nears 8500; Lupin, BHEL up

HDFC twins, Lupin, BHEL and Cipla are top gainers in the Sensex while Hindalco, Tata Motors, Coal India, Wipro and Maruti are among losers. The market somersaulted into green with some smart gains. The Sensex is up 159.14 points or 0.6 percent at ...
 Press Release Ping17 hours ago Bulls day: Sensex at 28000, Nifty on fire; Cipla gains 3%  Money Control2 days ago After flat start; Sensex slips into red  India Infoline3 weeks ago Blazing heat on D-Street: Sensex Nifty surge 2%, banks up  Money Control1 month ago

Initiate sell on Cipla as risks outweigh likely rewards

Cipla's decade-long effort on inhaler development may finally bear fruit over the next five years. However, based on management attrition and uncertainties in the inhalers space, the stock at CMP has limited room for an upside. Cipla has been late ...
 Financial Express2 days ago

Newsmaker: Kamil Hamied

Kamil Hamied, the 33-year-old scion of Cipla, has quit the pharmaceutical major at a time when the family patriarch, Cipla Chairman Yusuf Hamied, was finalising the plans to anoint him his successor and was grooming him to take over the reins of the ...
 Business Standard India1 week ago
Rediff.com

Samina Vaziralli set for bigger role in Cipla as scion Kamil quits

In a surprise move, Kamil Hamied, the successor of the Hamied family in pharmaceutical major, Cipla, has stepped down from the pharmaceutical company to pursue personal interests. Kamil's elder sister, Samina Vaziralli has taken on an expanded role ...
 Smart Investor1 week ago Cipla heir apparent Kamil quits, bigger role for sister Samina  Business Standard1 week ago Cipla heir apparent Kamil steps down  Rediff.com1 week ago Cipla heir apparent Kamil resigns, sister takes charge  The Financial Chronicle1 week ago
[x]  
Livemint.com

Cipla to enter 30 new markets in next two years

Cipla Ltd is set to enter 30 new international markets over the next two years as the drug maker plans to double its revenue from overseas markets. Chief executive Subhanu Saxena, who joined Cipla in 2012, said the company has already entered 17 ...
 Livemint.com1 week ago Cipla to enter 30 new markets in two years [Mint, New Delhi]  Bloomberg1 week ago
Livemint.com

Opening Bell | Watch out for Indiabulls, Cipla, SBI

A file photo of the BSE building in Mumbai. Photo: Bloomberg Greece worries continue to haunt market Asian markets were trading marginally higher on Monday morning as Greece continued to avoid agreeing to a deal to release €7.2 billion in ...
 Livemint.com1 week ago Opening Bell | Global equities mixed, pharma stocks in focus  Livemint.com2 weeks ago
First Post.com

India's Cipla expects to double respiratory drug sales by 2020 [Global Data Point]

More than a decade after it made headlines globally for offering to make AIDS drugs costing less than $1 a day, the company that was a pioneer in India's development as a force in generics is now working on producing cheaper medicines for ...
 Pharmacy Choice1 week ago India's patent regime should not change Cipla CEO  Reuters India2 weeks ago Cipla, BMS settle Hepatitis B drug dispute out of court  Financial Express2 weeks ago Interview  First Post.com2 weeks ago
[x]  
Med India

Cipla receives FDA approval for HIV drug

Cipla Limited, a biotechnology company, has received the FDA approval for Lopinavir/ ritonavir, or LPV/r, 40mg/ 10mg oral pellets, for treatment of HIV in infants. The pellets are to be sprinkled on sweetened porridge for infants and administered to ...
 Individual.com2 weeks ago FDA Approves Cipla's Drug Delivery System for Infants and Children Suffering from HIV  Med India4 weeks ago Cipla gets USFDA nod for Lopinavir, Ritonavir oral pellets  Business Standard1 month ago Cipla gets US FDA nod for Paediatric Lopinavir & Ritonavir Oral Pellets  India Infoline1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - cipla
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less